In medulloblastoma cells, it has been observed that a subpopulation of CD114+ cells presented altered growth, chemoresistance, and responsiveness to the granulocyte colony-stimulating factor (G-CSF): a drug sometimes used in cancer treatments, including medulloblastomas [7]. This evidence concerns the gene CSF3R and medulloblastoma.